<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endovenous intervention for iliocaval venous obstruction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endovenous intervention for iliocaval venous obstruction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endovenous intervention for iliocaval venous obstruction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albeir Y Mousa, MD, FACS, MBA, MPH, RPVI</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H278614083"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Iliocaval venous obstruction (ICVO) is an underrecognized venous outflow condition that can present with clinical features of chronic venous hypertension and chronic venous insufficiency, or with acute venous occlusion typically leading to extensive deep vein thrombosis (DVT). </p><p>Advancements in endovascular techniques have revolutionized the options for treating ICVO and are reviewed here. Whether to proceed with treatment depends upon the etiology of obstruction, severity of symptoms, and the presence or absence of thrombus (ie, thrombotic versus nonthrombotic ICVO). The clinical features, diagnosis, and approach to management of IVCO are reviewed separately [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/15223.html" rel="external">"Overview of iliocaval venous obstruction"</a>.) </p><p class="headingAnchor" id="H93370062"><span class="h1">PROCEDURE OVERVIEW</span><span class="headingEndMark"> — </span>Endovascular procedures used to treat iliocaval venous obstruction (ICVO) are typically performed in an interventional suite (eg, radiology, cardiovascular) or hybrid operating room using monitored conscious sedation. More advanced anesthetic techniques may be appropriate in selected cases. (See  <a class="medical medical_review" href="/z/d/html/102831.html" rel="external">"Considerations for non-operating room anesthesia (NORA)", section on 'Vascular procedures'</a>.)</p><p>Intervention for ICVO is undertaken in a stepwise fashion, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Gaining initial access to the venous circulation. (See <a class="local">'Potential sites for vein cannulation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Performing initial venography to confirm the level and location of venous obstruction and also to define the presence and the extent of any thrombus. Although the patient is likely to have had a venous duplex ultrasound (VDU) that identified a high likelihood of thrombus, the ability to fully characterize the obstruction with VDU can be limited due to a variety of factors (eg, body habitus, vein depth, overlying bowel gas). (See <a class="local">'Procedural imaging'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administering intravenous heparin for any identified thrombus or stenosis (weight-based dosing: 50 units/kg; partial thromboplastin time [PTT] target 1.5 to 2 times the upper limit of normal). For heparin allergy, alternative parenteral anticoagulants (eg, <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a>, <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a>) can be used. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/118004.html" rel="external">"Management of heparin-induced thrombocytopenia (HIT) during cardiac or vascular surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reducing the burden of thrombus from the venous system, typically using a combined approach with pharmacologic thrombolysis and mechanical thrombectomy (ie, pharmacomechanical thrombolysis). (See <a class="local">'Options for reducing thrombus burden'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using intravascular ultrasound (ideal if available) to confirm and characterize the degree of stenosis and for determining measurements for stent placement. (See <a class="local">'Procedural imaging'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Performing angioplasty/stenting of stenotic venous lesions and completion venography to confirm unobstructed venous patency and optimal stent positioning. (See <a class="local">'Angioplasty/stenting'</a> below and <a class="local">'Procedural imaging'</a> below.)</p><p></p><p>Vascular access is generally via the right or left common femoral vein and/or right internal jugular vein. A venogram showing the inferior vena cava (IVC) and both common iliac veins is obtained to locate and calibrate the area(s) of stenosis/occlusion. Intravascular ultrasound (IVUS) should be part of routine intraoperative assessment of any iliocaval pathology to precisely evaluate the proximal and distal extent of stenosis, to determine the actual diameter of the vessels, and finally to evaluate for any filling defects. Once the lesion is crossed with wire, the pressure gradient across the stenosis can be obtained (≥4 mmHg is significant in the IVC, &gt;2 mmHg is significant in the iliac veins).</p><p>Balloon angioplasty is performed using a noncompliant balloon (eg, 6 x 40 mm) prior to angioplasty to facilitate stent placement, typically with stainless steel stents (eg, Gianturco Z stent, Wallstent, Venovo, balloon expandable Palmaz stent).</p><p>Post-stent ballooning is carefully performed to achieve proper iliocaval venous dilation. The balloon is undersized and slowly inflated. Overdilation or rapid inflation can cause caval rupture. Following stenting, a completion venogram as well as IVUS exam confirms adequate angioplasty/stenting and rules out any extravasation or venous webbing. </p><p>Following venous stenting, dual antiplatelet therapy (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 81 mg and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily) is maintained for 12 weeks, thereafter aspirin 81 mg each day is continued indefinitely.</p><p class="headingAnchor" id="H3920578808"><span class="h1">TIMING OF TREATMENT</span><span class="headingEndMark"> — </span>The severity of symptoms is the primary driver for intervention. (See  <a class="medical medical_review" href="/z/d/html/15223.html" rel="external">"Overview of iliocaval venous obstruction", section on 'Approach to venous intervention'</a>.)</p><p>For thrombotic iliocaval venous obstruction (ICVO), while most studies of the efficacy of thrombolytic therapy have used ≤14 days as a limit for treating acute thrombus [<a href="#rid2">2-11</a>], duration of symptoms, rather than the documented duration of thrombosis, is probably more important. In many interventional practices, clinicians intervene for thrombotic venous obstruction for several weeks from the onset of acute symptoms. We agree with guidelines from the Society for Vascular Surgery that state "on balance, recommendations for consideration of early thrombus removal strategies in patients with symptoms of &lt;14 days of duration would seem fairly secure, although a benefit in patients with a duration of symptoms of &gt;14 days cannot be excluded" [<a href="#rid2">2</a>]. Some clinicians may elect to pursue thrombolysis in selected patients even after several months if symptoms are severe and risks are judged to be low (eg, young, otherwise healthy patient with minimal risk of bleeding). The outcomes of treatment of longer duration thrombus and chronic venous disease (eg, post-thrombotic syndrome) are not as good as those for treatment of more acute disease. (See <a class="local">'Outcomes'</a> below.) </p><p class="headingAnchor" id="H31621797"><span class="h1">POTENTIAL SITES FOR VEIN CANNULATION</span><span class="headingEndMark"> — </span>The approach to vein cannulation is made on a case-by-case basis and depends, in part, upon the extent of thrombus, if present, and the potential location of the stenotic venous lesion(s). The clinician needs to decide among the potential sites for vein cannulation and whether to approach ipsilateral or contralateral (ie, up-and-on over) to the clinically affected side. Routine real-time ultrasound-guided venous access is recommended during vein cannulation because it improves time to access and reduces the number of unsuccessful attempts and inadvertent arterial puncture, which are particularly relevant for reducing complications related to administration of pharmacologic thrombolytic agents (eg, hematoma). (See  <a class="medical medical_review" href="/z/d/html/6315.html" rel="external">"Basic principles of ultrasound-guided venous access"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>If the diseased segment is located in the inferior vena cava (IVC) or iliac veins, we generally approach from the groin. This includes thrombotic or nonthrombotic conditions. (See <a class="local">'Femoral approach'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the diseased segment includes the iliocaval segment and common femoral veins with or without femoropopliteal thrombus, we generally approach from the ipsilateral popliteal region, or possibly tibial region depending upon the extent of thrombus. However, a contralateral approach may be considered for achieving an unobstructed pathway from proximal to distal (cranial to caudal) in cases of extensive thrombosis. (See <a class="local">'Popliteal approach'</a> below.)</p><p></p><p>For patients with acute thrombus, a thrombolysis catheter can be placed to initiate thrombolytic therapy. For chronic iliocaval occlusion or following thrombolysis that reveals a persistent stenotic segment, the access sheath(s) will need to be "upsized" to a larger size (eg, up to 12 Fr sheath) to accommodate the necessary devices, balloons, and stents. (See <a class="local">'Options for reducing thrombus burden'</a> below and <a class="local">'Angioplasty/stenting'</a> below.)</p><p class="headingAnchor" id="H2013177051"><span class="h2">Femoral approach</span><span class="headingEndMark"> — </span>For iliocaval venous obstruction (ICVO) proximal (cranial) to the inguinal ligament, we position the patient supine. Both groins are prepared and draped in standard surgical fashion. Using ultrasound guidance, the common femoral veins are accessed bilaterally using a micropuncture kit, preferably at the saphenofemoral junction. The micropuncture sheath is upsized to an 8 Fr sheath and the patient is anticoagulated (eg, <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>; 50 units/kg).</p><p>Bilateral iliac venograms are obtained using both anteroposterior and oblique views to evaluate the iliocaval segment. A glidewire is introduced through a guiding catheter to navigate through the iliocaval segment. Stiff-straight or stiff-angled glidewires may be needed. After confirming that the wire is in a segment of the inferior vena cava that is free from thrombus or stenosis, the glidewire is exchanged for a stiff, working wire (eg, Supracore). </p><p class="headingAnchor" id="H285316473"><span class="h2">Popliteal approach</span><span class="headingEndMark"> — </span>For ICVO that involves the common femoral vein(s), with or without thrombosis, we generally position the patient prone to access the popliteal vein(s) or possibly tibial vein(s). Alternatively, if the contralateral iliofemoral veins are not involved, an up-and-over groin approach can be used. (See <a class="local">'Femoral approach'</a> above.)</p><p>The popliteal fossae bilaterally are prepared and draped in standard fashion. The popliteal vein ipsilateral to the diseased iliac segment is accessed using a micropuncture technique with ultrasound guidance. The micropuncture sheath is upgraded to a 5 or 6 Fr sheath and the patient is anticoagulated (eg, <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>; 50 units/kg). A glidewire can be used to navigate through the occluded segments of the femoral, common femoral, and iliac veins, and inferior vena cava. After crossing all occluded segments, the intraluminal position of the wire is confirmed on venogram. </p><p class="headingAnchor" id="H2111692084"><span class="h1">PROCEDURAL IMAGING</span><span class="headingEndMark"> — </span>Once venous access is achieved, venography with adjunctive intravascular ultrasound (IVUS) is used to confirm the diagnosis of iliocaval venous obstruction (ICVO), aid in positioning devices, measure the vein to ensure proper stent sizing, and evaluate the results of intervention. </p><p class="headingAnchor" id="H2419046041"><span class="h2">Venography</span><span class="headingEndMark"> — </span>Contrast venography, particularly with the added use of transvenous pressure measurements, confirms the preintervention ultrasound diagnosis of ICVO and provides insight toward chronicity of lesions. Chronic lesions will be resistant to balloon angioplasty. Venography also identifies any variations, such as a duplicated or rudimentary venous system  (<a class="graphic graphic_figure graphicRef95452" href="/z/d/graphic/95452.html" rel="external">figure 1</a>). </p><p>Venography for caval lesions can be performed with a pigtail catheter using a pressure injector (600 psi) to bolus intravenous contrast (eg, Visipaque). Obtaining two or three different projections with a pigtail catheter in the external iliac vein may improve the accuracy of venography. However, for more distal (caudal) lesions, it may be equally effective to perform hand-injected venography through the access sheath in the femoral position rather than using a power injector.</p><p>Obtaining invasive hemodynamic pressure measurements is a valuable adjunct for confirming iliocaval venous stenosis. Simultaneous pressure measurements from both iliac veins can be obtained and compared. A pressure gradient of &gt;2 mmHg can be used to diagnose significant stenosis [<a href="#rid12">12</a>]. Using a pullback method comparing the pressure in the inferior vena cava above the obstruction site with the pressure below the obstruction may be more accurate [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H3347111411"><span class="h2">Intravascular ultrasound</span><span class="headingEndMark"> — </span>IVUS, if available, can be performed after the initial venography. A high-frequency ultrasound transducer located directly on the tip of a catheter provides the operator with a real-time, cross-sectional image that can be used to examine the target vessel. Since its inception and with increasing use over the last decade, IVUS has become the single most important advancement in the evaluation and treatment of ICVO [<a href="#rid14">14</a>]. IVUS has become integral to stent deployment by providing accurate diameters for diseased and undiseased segments and for assessing any residual post-stenting stenosis. IVUS can also be used to locate the lowest renal vein during deployment of stents in the inferior vena cava or to estimate the degree of recanalization in those with post-thrombotic syndrome.</p><p>Several IVUS devices are available that vary in the type of transducer or catheter. For the iliocaval segment, a relatively "low" frequency catheter ultrasound transducer provides an acceptable balance between tissue penetration and high resolution. Several catheters are available for iliocaval imaging that use a 0.035 inch wire platform (eg, Volcano [60 mm, 10 MHz], Opticross [30 mm, 15 MHz], Sonicath [50 mm, 9 MHz]).</p><p>After initiating systemic anticoagulation with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>, the IVUS catheter is introduced through an 8 Fr sheath and connected to the intravascular ultrasound system (eg, Volcano S5). </p><p>IVUS should ideally be performed from both groin access locations to assess the iliac veins bilaterally. The orientation of intravascular ultrasound should be adjusted to identify the overlying iliac arteries. A slow pullback technique will precisely record the degree, extent, and nature of stenosis/thrombosis. </p><p class="headingAnchor" id="H1060905334"><span class="h1">THROMBOLYSIS</span><span class="headingEndMark"> — </span>Advancements in endovenous treatments have been instrumental in improving outcomes, particularly among those with thrombotic iliocaval venous obstruction (ICVO) [<a href="#rid15">15</a>]. A well-balanced discussion with the patient prior to intervention is important to convey the benefits/risks of treatment. The patient must understand all risks, including the risk of bleeding, compared with the potential benefit of a decreased chance of post-thrombotic syndrome. </p><p class="headingAnchor" id="H1309056468"><span class="h2">Options for reducing thrombus burden</span><span class="headingEndMark"> — </span>One or a combination of endovascular techniques can be used to reduce the burden of thrombus when it is encountered [<a href="#rid2">2,16-25</a>]. Available options include catheter-directed thrombolysis (CDT), mechanical thrombectomy, or a combination (ie, pharmacomechanical thrombolysis). </p><p>CDT selectively administers the thrombolytic agent into the thrombus and is often the first line of treatment [<a href="#rid2">2,16,17</a>]. We prefer the added benefits of mechanical thrombectomy, which helps to fractionate the thrombus load, thus facilitating the action and increasing the surface area for the pharmacologic agent to work. While limited data have demonstrated significant clearing of thrombus (&gt;50 percent) in one-third of patients treated with mechanical thrombectomy alone, it is not generally recommended without a concurrent thrombolytic agent [<a href="#rid26">26</a>]. Mechanical thrombectomy alone frequently leads to rethrombosis. Although, a multicenter study of 15 patients using the ClotTriever and FlowTriever devices demonstrated adequate treatment of thrombotic iliocaval lesions without the use of thrombolytic drugs [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H972252999"><span class="h3">Catheter-directed pharmacologic thrombolysis</span><span class="headingEndMark"> — </span>CDT is an important advance in the treatment of ICVO, particularly extensive proximal lower extremity deep vein thrombosis (DVT). CDT involves placement of a catheter into the thrombus. The main benefit of catheter-directed treatment is the delivery of concentrated drug directly at the thrombus site to dissolve the thrombus. In addition, mechanical disruption of the thrombus helps to increase the surface area, thereby augmenting the effect of the thrombolytic agent. If dissolution of the thrombus uncovers an underlying venous stenosis, treating it may help prevent rethrombosis. </p><p>Two methods are available for CDT and include the pulse spray techniques and ultrasound-assisted thrombolysis (eg, EkoSonic Endovascular System [EKOS]). Pulse spray can be started after placement of an adequate treatment zone multi-side hole catheter (eg, Unifuse, Mewissen; typically 50 cm) connected to a standard infusion pump to deliver the thrombolytic agent at a specific rate to a set dose. Ultrasound-assisted CDT also uses a multi-side hole catheter to deliver the thrombolytic agent, but a core wire, which emits high-frequency, low-intensity ultrasound, is included as a part of the catheter system. The ultrasound energy aims to disaggregate fibrin fibers, increase available surface area within the thrombus, and permit greater penetration of the thrombolytic agent. Outcomes for these two catheters are comparable [<a href="#rid28">28</a>]. The choice is guided by the operator's experience. </p><p class="headingAnchor" id="H4085784873"><span class="h3">Percutaneous mechanical thrombectomy</span><span class="headingEndMark"> — </span>Mechanical thrombectomy uses a variety of devices to break up thrombus with or without the aid of pharmacologic agents. Outcomes using mechanical thrombectomy alone have been dismal; however, for patients with extensive DVT and candidates for treatment, but in whom pharmacologic thrombolysis is contraindicated, mechanical thrombectomy by itself can be considered. Available devices include: </p><p class="bulletIndent1"><span class="glyph">●</span>Rheolytic thrombectomy – Rheolytic thrombectomy injects high-velocity <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> using Bernoulli's principle to break up and aspirate clot (eg, Angiojet-Zelante [8 Fr], Angiojet-Solent [6 Fr]) [<a href="#rid29">29</a>]. Devices are placed over a 0.035 inch wire.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rotational thrombectomy – Rotational thrombectomy macerates thrombus using a rotating sinusoidal wire (eg, Cleaner-XT [6 Fr] and Cleaner-15 [7 Fr]) [<a href="#rid30">30</a>]. No guidewire is needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suction thrombectomy – For suction thrombectomy, a steerable delivery catheter provides a high-velocity vacuum suction to aspirate thrombus (eg, Penumbra: 4, 6, 8, and 12 Fr; ClotTriever funnel sheath: 13 Fr with catheter 13 to 25 mm [<a href="#rid27">27,31</a>]). These catheters are designed to facilitate debulking and removal of significant amounts of acute thrombus (&lt;4 weeks) from larger veins without the need for pharmacologic agents [<a href="#rid27">27,31</a>]. These catheters can offer lytic free clot retrieval in one session. However, clot needs to be fresh to be suctioned completely. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The ClotTriever consists of two pieces, a 13 Fr sheath equipped with a funnel at the proximal end (ie, the ClotTriever catheter) and a large-bore hemostatic valve with a large suction syringe attached designed to facilitate clot removal in concert with the funnel device. The catheter incorporates a retractable coring element that, when deployed, is designed to capture thrombus from vessels up to 16 mm in diameter, and is then directed into a long collection bag that is withdrawn through the sheath for retrieval [<a href="#rid27">27,32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Indigo continuous aspiration mechanical thrombectomy (CAT) system is another aspiration mechanical thrombectomy device that intended to aspirate acute thrombus without the need for administration of thrombolytic medication, thereby reducing the risk of bleeding [<a href="#rid33">33</a>]. CAT is a single-use device for aspiration of arterial or venous thrombus in any vessel except for the coronary or cranial vessels. It has three components: a catheter, a separator, and a vacuum pump. Four catheter sizes are available from 3.4 Fr to 8 Fr). The CAT 8 (8 Fr), which is used mainly for venous thrombectomy, can aspirate up to 160 mL/s. It has an angulated tip for rotational use to clear larger thrombus burdens. The separator allows thrombus fragmentation and mobilization as well as cleaning of the catheter when it is obstructed by thrombus. The vacuum pump provides continuous suction by applying and maintaining negative pressure of 29 mmHg [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cannula and circuit thrombectomy – Circuit thrombectomy uses a large-caliber suction cannula and filter, which are spliced into an extracorporeal veno-venous bypass circuit to remove thrombus (AngioVac; 22 Fr); adjuvant rotational thrombectomy devices (eg, CLEANER, Aspirex, Vetex, ThromCat, FlowTriever Catheter) may also be used. </p><p></p><p class="headingAnchor" id="H2777973320"><span class="h3">Combined treatment: Pharmacomechanical thrombolysis</span><span class="headingEndMark"> — </span>For the treatment of thrombotic ICVO, we prefer to use a combination of pharmacological CDT and mechanical thrombectomy (ie, pharmacomechanical) thrombolysis. The added benefit of mechanical thrombolysis is to fractionate the load of the thrombus to facilitate the pharmacologic phase of therapy. Many studies have shown significant reduction in thrombolytic dosage, hospital stay, and intensive care unit utilization [<a href="#rid35">35,36</a>]. </p><p>Commercially available systems for pharmacomechanical thrombolysis include rotational (eg, Angiojet, Trellis), rheolytic, and ultrasound-assisted mechanical thrombectomy devices that also include a means by which to administer pharmacologic agents [<a href="#rid37">37-42</a>]. The mechanical aspects of these devices are similar to those described above. (See <a class="local">'Percutaneous mechanical thrombectomy'</a> above.) </p><p class="headingAnchor" id="H1947190501"><span class="h2">Prophylactic IVC filter</span><span class="headingEndMark"> — </span>Whether to place an inferior vena cava (IVC) filter before initiating thrombolytic therapy is controversial. The Society for Vascular Surgery (SVS) supports placement of IVC filters in selected patients, though it recommends against routine use. The decision to place a temporary IVC filter prior to pharmacomechanical thrombectomy should be based on individual patient risk factors and practitioner preference. Due to inherent long-term complications and reduced benefit after the first two weeks, the IVC filter should be retrieved as soon the indication for it no longer exists [<a href="#rid2">2,43-45</a>]. </p><p>Observational studies and one trial have suggested a potential benefit for prophylactic IVC filter placement to reduce the risk of fatal embolic complications in patients undergoing venous thrombolysis [<a href="#rid46">46,47</a>]. In the author's practice, a retrievable IVC filter is often placed prior to thrombolysis and angioplasty/stenting for ICVO  (<a class="graphic graphic_diagnosticimage graphicRef111783" href="/z/d/graphic/111783.html" rel="external">image 1</a>). Some clinicians do not place an IVC filter unless there has been significant prior PE. Proponents of not placing IVC filters point to the potential complications related to the filter itself, particularly when there is not a clear need for an ongoing/permanent filter and the filter is not retrieved. One trial evaluated the effect of IVC filter use during intervention [<a href="#rid48">48</a>]. In the Filter Implantation to Lower Thromboembolic Risk in Percutaneous Endovenous Intervention (FILTER-PEVI) trial, the use of a filter significantly lowered the risk of symptomatic PE compared with no filter (1 of 14 [1.4 percent] versus 8 of 22 [11.3 percent]) [<a href="#rid48">48</a>]. In the TORPEDO trial, 88 patients were randomly assigned to receive percutaneous endovascular venous intervention (PEVI), which included IVC filter placement, or to a control group who received only medical treatment [<a href="#rid49">49</a>]. Non-fatal PE was noted in three patients of the control group compared with none in the PEVI group, although this was not statistically significant. Fatal PE was noted in four patients of the control group versus one patient in PEVI group.</p><p>When prophylactic filter placement is chosen, it can be placed via the nondiseased common femoral vein or using a transjugular approach. The placement of IVC filters and retrieval of temporary filters are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8212.html" rel="external">"Placement of vena cava filters and their complications"</a>.) </p><p class="headingAnchor" id="H3748287212"><span class="h2">Thrombolytic agents and dosing</span><span class="headingEndMark"> — </span>Several thrombolytic agents are currently available. Streptokinase is the only thrombolytic agent approved for venous thrombolysis by the US Food and Drug Administration, but it is rarely used due to common side effects, including allergy and a higher risk of bleeding complications. Other thrombolytic agents such as recombinant tissue plasminogen activator (rtPA; <a class="drug drug_general" data-topicid="8478" href="/z/d/drug information/8478.html" rel="external">alteplase</a>, <a class="drug drug_general" data-topicid="9857" href="/z/d/drug information/9857.html" rel="external">reteplase</a>, <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">tenecteplase</a>) and urokinase are also available, and while these have indications primarily for arterial thrombolysis, they have been used extensively in the venous system [<a href="#rid26">26,41,50,51</a>]. The majority of reported experience has been with rtPA, but reteplase and tenecteplase have been reported in small case series. </p><p>Prior to the administration of the thrombolytic agent, a soft 0.035 inch guidewire and a guiding catheter are used to navigate through the occlusion, and when an intraluminal position is confirmed, the soft wire is exchanged for a stiff working wire (eg, Supracore). Sequential ballooning of the common iliac veins can be tried using 9 or 10 mm compliant balloons, which helps to increase the surface area for thrombolysis and to mechanically fracture and destabilize any organized thrombus.</p><p>Thrombolysis is started with an initial bolus dose of 2 to 4 mg tPA. After placement of the catheter with the patient positioned supine (or repositioned if the procedure started in the prone position), the infusion can be started. For pulse spray CDT with rtPA, accepted dosing is weight-based administration starting at 0.01 mg/kg/hr, not to exceed 1.0 mg/hr [<a href="#rid4">4,52</a>]. Low-dose heparin is administered concurrently (500 units/hour) to prevent thrombosis of the access sheath. The catheter should be firmly secured to the patient's leg before transportation to a monitored unit. (See <a class="local">'Monitoring'</a> below.)</p><p>Patients with contraindication to thrombolysis may be considered for mechanical thrombectomy. One study has showed improved functional outcomes even if thrombolysis therapy is contraindicated [<a href="#rid53">53</a>]. </p><p class="headingAnchor" id="H2242518303"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>While it is common to monitor a variety of hemostatic parameters during thrombolysis to reduce the risk of unwanted bleeding, there is a paucity of reliable data upon which to make definitive recommendations regarding monitoring. Many clinicians measure platelet counts, hemoglobin, fibrinogen, fibrin degradation products, and activated partial thromboplastin time prior to and after initiation of thrombolysis. One publication and associated commentary questioned the value the monitoring fibrinogen levels in patients with pulmonary embolism treated with CDT [<a href="#rid54">54,55</a>]. Suffice it to say that there is a significant need for improved methods to accurately predict the risk of bleeding in patients undergoing venous thrombolysis. </p><p>It is common practice to reduce or discontinue tPA in the setting of dropping or very low fibrinogen levels based on data derived from the coronary literature. Because a plasma fibrinogen level (PFL) &lt;100 mg/dL is associated with the occurrence of minor and major hemorrhagic complications [<a href="#rid56">56</a>], we usually monitor PFL and if the levels drop to &lt;150 mg/dL, we stop the thrombolytic infusion for two hours and repeat testing. If the PFL continues to be low and the patient is stable, we continue a heparin drip at 500 units/hour via the sheath and normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> at 20 cc/hour via the side-hole infusion catheter. If the PFL normalizes after two hours, thrombolytic therapy can be resumed [<a href="#rid57">57</a>].</p><p>The patient is reevaluated in the interventional suite at 24 hours, and additional balloon angioplasty is performed for residual stenosis, as needed. (See <a class="local">'Angioplasty/stenting'</a> below.)</p><p class="headingAnchor" id="H3650309626"><span class="h1">ANGIOPLASTY/STENTING</span><span class="headingEndMark"> — </span>For symptomatic iliocaval venous obstruction (ICVO) stenosis, stenting is preferable but is not universally agreed upon. Stenting is important for maintaining patent venous outflow in the long term [<a href="#rid2">2,58-65</a>]. Without stenting, recurrence rates are greater than 70 percent [<a href="#rid66">66</a>]. In addition, in the iliac segment, residual stenosis has been correlated to the development of post-thrombotic syndrome [<a href="#rid67">67</a>]. However, recurrence rates may depend upon underlying pathology and type of stent used [<a href="#rid66">66,68</a>]. </p><p>If thrombus is present on the initial venogram, angioplasty and stenting of a stenotic ICVO lesion can only be performed once thrombus has been cleared. Once vein patency is restored using pharmacomechanical thrombolysis, as confirmed by repeat venography, angioplasty and stenting can be undertaken. (See <a class="local">'Options for reducing thrombus burden'</a> above.)</p><p class="headingAnchor" id="H887684881"><span class="h2">Venous stents</span><span class="headingEndMark"> — </span>Using stents designed specifically for the venous system is of paramount importance in treating venous occlusive disease. Patency rates are overall high for venous stenting, particularly for nonthrombotic lesions. </p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of venous stents with at least 30 patients and six months or more follow-up primary, assisted primary, and secondary patency rates were 71, 89, and 91 percent, respectively, with a median follow-up of two years [<a href="#rid69">69</a>]. Higher patency was reported for nonthrombotic compared with thrombotic lesions (96 versus 73 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 90 consecutive patients treated using venous stents, one-year primary, assisted primary, and secondary patency rates were 92.2, 92.2, and 93.9 percent, respectively [<a href="#rid70">70</a>]. Venous Clinical Severity Scores were also improved. Stent patency was significantly lower for thrombotic venous lesions compared with nonthrombotic lesions (86 versus 100 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a pivotal study, 170 symptomatic patients (CEAP II or III) with a mean diameter stenosis of 78 percent underwent treatment with a self-expanding nitinol venous stent [<a href="#rid71">71</a>]. Among 127 patients with chronic post-thrombotic obstruction, mean lesion length was 125.3 mm. Initial technical success was high, and freedom from major adverse events through 30 days was 98.8 percent. The one-year primary patency rate for the entire group was 84 percent and was lower for chronic post-thrombotic disease (79.8 versus 96.2 percent).</p><p></p><p>It is important to consider specific stent characteristics, such as foreshortening, radial pressure, and collapse. Knowledge of the maximal foreshortening of the initial length is imperative for planning stent placement and coverage. In one review, maximal foreshortening values for three venous stents were: 11.3 percent of the Cook Z stent, 14.2 percent for the Cook Vena stent, and 88.7 percent for the Wallstent. While subject to more foreshortening, steel stents (eg, Wallstent) have more radial force and are less compliant compared with nitinol stents (Cook Z), and therefore may be more useful for treating pinch force lesions such as those found in May-Thurner syndrome [<a href="#rid72">72</a>].</p><p>Stent failure is mainly related to technical factors, such as new or missed stenosis in native iliac vein, inadequate stent expansion, or the use of unilateral iliac stent that extends into the inferior vena cava (IVC) obstructing flow from the contralateral iliac vein [<a href="#rid73">73</a>]. Yet, there is a role for using pharmacological adjuncts to maintain stent patency. To optimize patency, the authors of a respected study suggested that without substantial evidence to demonstrate efficacy for stents in venous occlusive disease, the use of adjunct antiplatelets in primary nonthrombotic lesions and the consideration of anticoagulant in thrombotic ones appears to be reasonable [<a href="#rid74">74</a>]. (See <a class="local">'Antithrombotic therapy'</a> below.)</p><p class="headingAnchor" id="H1852451045"><span class="h2">General technique</span><span class="headingEndMark"> — </span>Once the vein is clear of thrombus, if it was present, intravascular ultrasound (IVUS) is used to characterize the location and severity of stenotic lesions and to calibrate the size of the vein before stent placement. A self-expanding stent is typically used and positioned in the region of the stenosis. The stent diameter is chosen to be 20 percent larger than the normal vein diameter. In the author's practice, stent diameter sizes are typically between 12 and 24 mm, depending on the size of the target vein. Once deployed, the stent is dilated using a balloon to open the stent with a 1:1 ratio (ie, no oversizing). (See <a class="local">'Intravascular ultrasound'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>For cases in which a thrombosed IVC filter is encountered, the filter can be crossed with a guidewire and in some cases will respond to a high-pressure balloon. At other times, a second stent may be needed. The second stent (eg, Wallstent) will crush and displace the occluded IVC filter laterally. Special attention needs to be given to the renal veins and every effort made to stay below them. Suboptimal results may require deployment of a balloon-expandable stent (eg, Palmaz stent P4010) mounted onto a 14 to 18 mm balloon (eg, Maxi LD) to provide sufficient radial force to maintain the lumen of IVC. Placing a "kissing stent" (self-expanding) distally (caudally) into each common iliac vein completes treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior to iliac vein stenting, a 10 mm noncompliant balloon can be used to predilate the lesion. For a more distal (caudal) lesion, a smaller noncompliant balloon can be used. Following angioplasty, it is imperative to stent all diseased segments. At times, it may be necessary to extend the stent to or below the inguinal ligament to recanalize the iliofemoral segment. If there is a technical need, interventionists should be careful about extending a standard stent with small interstices (eg, Wallstent) into the IVC due to the possibility of jailing the contralateral common iliac vein [<a href="#rid68">68,75-77</a>]. A later-generation stent with larger interstices (eg, Gianturco Z-stent) has been designed for this situation to minimize the impedance to venous flow by the protruding stent, and it may also help maintain patency by reinforcing the iliocaval junction [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the femoropopliteal segment is involved, a long balloon (eg, 5 mm x 10 cm) can be used to angioplasty the vein from proximal to distal (cranial to caudal). Stenting the femoropopliteal vein segment may also be needed; however, every effort should be made not to cover the confluence of the deep femoral vein. </p><p></p><p>Completion venography along with IVUS examination is necessary to confirm the adequacy of treatment. Successful recanalization in our practice is defined with residual stenosis &lt;30 percent (any site; IVC, iliac, femoral, popliteal); still, some respected authorities consider &lt;50 percent as satisfactory [<a href="#rid79">79</a>].</p><p>Following stenting, antiplatelet therapy is initiated immediately. (See <a class="local">'Antithrombotic therapy'</a> below.)</p><p class="headingAnchor" id="H1769350790"><span class="h2">Specific techniques</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanical thrombectomy</strong> –<strong> </strong>With the patient in the prone position, ultrasound-guided access of the popliteal vein is obtained, upgrading to an 8 Fr sheath. The patient is systemically anticoagulated typically with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (80 units/kg) or an alternative agent (eg, Angiomax) for those with contraindications. Venography is performed to confirm the presence and extent of deep vein thrombosis. Intravascular ultrasound (IVUS) can be used as well to delineate the extent of thrombotic lesion and any possible underlying pathology. An exchange length guidewire (eg, Supracore) is placed, and at this time, the sheath is exchanged for 13 Fr ClotTriever sheath, and the ClotTriever catheter is inserted over the guidewire and positioned in the IVC. The nitinol basket bag is deployed, the device is withdrawn through the thrombotic segment, and thrombus is extracted and removed via the 13 Fr sheath. Multiple passes (in author's experience up to six passes) may be required, and there is no limit to how many times it can be used. The nitinol basket is very durable, so it can be easily removed, cleaned, resheathed, and redeployed. Final venography and IVUS confirm patency and identify any underlying pathology such as May-Thurner syndrome that requires angioplasty and stenting. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stent placement and orientation</strong> – Several options are available for stenting chronic iliocaval venous obstruction and include placement of two stents side by side (double-barrel stent), the inverted Y stent in which another iliac stent is deployed through a "fenestration" of previous stent across the caval confluence, and stent apposition as close as possible to the previously deployed stent at the caval confluence. One review evaluated stent technique for 230 limbs with ICVO, the authors concluded that the barrel technique was optimal and should be performed, if feasible. A high number of reinterventions were reported for the apposition technique.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whether to cover the contralateral iliac vein ostium</strong> – Covering the contralateral iliac vein during unilateral IVCO is a valid concern. In a review of 261 patients (177 nonthrombotic, 84 thrombotic), stent placement for nonthrombotic ICVO [<a href="#rid80">80</a>] had 97 percent long-term primary patency rate and 100 percent assisted primary patency rate. Encroachment of the contralateral iliac vein was relatively safe with &lt;1 percent of those who had a stent placed ≥5 mm into the confluence of IVC developing a thrombotic event at a median follow up of 62 months.</p><p></p><p class="bulletIndent1">Another systematic review [<a href="#rid81">81</a>] of 12 studies with total 1864 patients reported incidence of contralateral iliac vein thrombosis up to 15.6 percent. In the author's opinion, incidence of contralateral iliac vein thrombosis in the event of partially or totally covering the confluence of IVC is not negligible, and every effort should be pursued not to cover the contralateral ostium of iliac vein, and if that accidentally occurs, a long-term antithrombic medications should be considered, if feasible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iliocaval venous anomalies</strong> – Iliocaval venous anomalies (ICVAs) are not uncommon and often encountered during venogram. It is imperative to be aware of them since they may be more prevalent than previously thought. In one study, the prevalence of ICVAs was 15 percent (129 of 845 patients) [<a href="#rid82">82</a>]. A high IVC confluence occurred (bifurcation was above L4-L3 disc space) in 56 percent of patients, followed by right internal iliac vein draining into proximal left common iliac vein in 22.5 percent and double IVC in 8.5 percent. This review highlights the importance of performing a full venogram prior to any angioplasty/stenting. While IVUS is critical to calibrate area of stenosis/obstruction, it may not be adequate to evaluate the venous bed prior to stenting.</p><p></p><p class="headingAnchor" id="H225037158"><span class="h2">Example cases</span><span class="headingEndMark"> — </span>May-Thurner Syndrome (MTS) is a common underlying cause of ICVO, but other etiologies should be considered as well. The following cases illustrated the author's practice. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic May-Thurner syndrome</strong> — A young female in her early twenties presented with acute deep vein thrombosis  (<a class="graphic graphic_diagnosticimage graphicRef111781" href="/z/d/graphic/111781.html" rel="external">image 2</a>). Magnetic resonance angiography was suspicious for MTS  (<a class="graphic graphic_diagnosticimage graphicRef111782" href="/z/d/graphic/111782.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef111784" href="/z/d/graphic/111784.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef111785" href="/z/d/graphic/111785.html" rel="external">image 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilateral May-Thurner syndrome </strong>–<strong> </strong>A female in her early thirties with severe bilateral lower extremity swelling and bilateral venous claudication. Following bilateral iliac vein stenting, venography showed resolution of venous collaterals  (<a class="graphic graphic_diagnosticimage graphicRef112058" href="/z/d/graphic/112058.html" rel="external">image 6</a>), and IVUS showed resolution of the stenoses  (<a class="graphic graphic_movie graphicRef112060" href="/z/d/graphic/112060.html" rel="external">movie 1</a> and <a class="graphic graphic_movie graphicRef112061" href="/z/d/graphic/112061.html" rel="external">movie 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric May-Thurner syndrome</strong> – Adolescent female with thrombotic May-Thurner syndrome  (<a class="graphic graphic_diagnosticimage graphicRef111787" href="/z/d/graphic/111787.html" rel="external">image 7</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired May-Thurner syndrome</strong> – Older male presenting with acute DVT after remote history of endovascular aortic aneurysm repair  (<a class="graphic graphic_diagnosticimage graphicRef111788" href="/z/d/graphic/111788.html" rel="external">image 8</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IVC filter thrombosis </strong>–<strong> </strong>Older female<strong> </strong>with prior history of DVT and filter placement with extensive swelling  (<a class="graphic graphic_diagnosticimage graphicRef116565" href="/z/d/graphic/116565.html" rel="external">image 9</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-thrombotic syndrome with IVC stenosis</strong> – Older male with bilateral with bilateral post-thrombotic syndrome and IVC filter stenosis  (<a class="graphic graphic_diagnosticimage graphicRef116564" href="/z/d/graphic/116564.html" rel="external">image 10</a>). </p><p></p><p class="headingAnchor" id="H857547741"><span class="h1">POSTPROCEDURE CARE AND FOLLOW-UP</span><span class="headingEndMark"> — </span>After completion of the endovascular intervention and before leaving the interventional suite, compression dressings are placed to augment venous drainage once the outflow obstruction is relieved. Special attention should be paid to maintaining adequate elevation of the foot of the bed to at least 30° and also in using bilateral sequential pneumatic compression devices. Early ambulation is recommended.</p><p>Follow-up appointments are scheduled for one, three, and six months postprocedure, then annually thereafter. At each office visit, a full clinical examination is performed to document level of activity and the presence and degree of any limb swelling, skin changes, and progress of any venous ulcer healing. Vascular imaging is indicated for any recurrence of symptoms.</p><p class="headingAnchor" id="H2726398985"><span class="h2">Antithrombotic therapy</span><span class="headingEndMark"> — </span>Even among experts in the field, there is no consensus on the optimal type and duration of antithrombotic regimen after angioplasty and stenting for venous occlusive disease. There are no data from randomized trials to guide decisions on antithrombotic therapy, and as a result, clinical practice varies widely [<a href="#rid74">74,83-87</a>]. Our general approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with <strong>acute</strong> iliocaval venous thrombosis (ie, thrombotic) should receive therapeutic anticoagulation with dosing, and duration as per venous thromboembolism (VTE) guidelines [<a href="#rid2">2,88,89</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who undergo venous angioplasty, but no stent has been deployed, we suggest <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (81 mg) daily. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who undergo venous stenting at low risk for bleeding, we suggest <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> for a period of four to six weeks, then <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> indefinitely. (See <a class="local">'Our approach after venous stenting'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with <strong>chronic</strong> iliocaval venous disease (ie, nonthrombotic), after a stent has been deployed, we suggest dual antiplatelet therapy with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> in addition to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for four to six weeks, then aspirin indefinitely. (See <a class="local">'Our approach after venous stenting'</a> below.)</p><p></p><p>For those with an increased risk for bleeding, antiplatelet therapy is individualized but often consists of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone. We suggest not using triple antithrombotic therapy (ie, anticoagulation and dual antiplatelet therapy) because of its inherent increased risk of major bleeding. Anticoagulation options, dosing and the duration of therapy for patients with deep vein thrombosis (DVT) are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at low risk of bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p class="headingAnchor" id="H1095060615"><span class="h3">Variability of use after venous intervention</span><span class="headingEndMark"> — </span>While there is little debate over the need for ongoing anticoagulation among those who undergo venous intervention for thrombotic disease (acute, post-thrombotic), the need for and selection of antithrombotic therapy for nonthrombotic disease is controversial. Some believe the role for antiplatelet therapy is less for the slower flow/lower shear venous system compared with the arterial system [<a href="#rid74">74,90</a>]. However, generally speaking, the vascular response to stent placement in the venous bed is similar to stented arteries, with endothelial injury activating the coagulation cascade at the site of stenting [<a href="#rid91">91</a>] and inflammatory changes promoting neointimal hyperplasia [<a href="#rid92">92-94</a>]. The evidence supporting the use of antiplatelet agents is largely indirect and extrapolated from recommendations for antiplatelet therapy based on studies demonstrating improved patency of arterial stents [<a href="#rid74">74,95-99</a>]. However, studies evaluating specific antithrombotic regimens following venous stenting are emerging. As in arterial disease, the goal of antithrombotic therapy following venous stenting is to maintain long-term patency of the revascularization and to mitigate adverse systemic outcomes. </p><p>The variability in practice is illustrated in the following review that examined the antithrombotic regimen used in 151 patients following iliac vein stenting [<a href="#rid100">100</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Thirty-eight percent received triple therapy (anticoagulation plus dual antiplatelet therapy), 17 percent received anticoagulation only, 14 percent received anticoagulation plus a single antiplatelet agent, 10 percent received dual antiplatelet therapy only, 7 percent received a single antiplatelet agent, and 15 percent received no antithrombotic therapy. Not surprisingly, those with acute DVT and those with a prior history of DVT were more likely to be anticoagulated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The duration of antithrombotic therapy was also variable. When anticoagulation was prescribed (104 patients), 31 percent received indefinite therapy, 22 percent were anticoagulated for six months, and 12 percent were anticoagulated for three months. Patients with a history of prior DVT or thrombophilia were more likely to be prescribed indefinite anticoagulation. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> was the most common agent used for an indefinite duration (62 of 88 patients), while it was common to prescribe <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> for just three months (60 of 89 patients). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Triple antithrombotic therapy (anticoagulation with dual antiplatelet therapy) significantly reduced the odds of experiencing in-stent stenosis/stent thrombosis when compared with dual antithrombotic therapy, but pairwise comparisons of the remaining treatment groups did not yield significant differences. Whether triple therapy improved the odds of in-stent restenosis/stent thrombosis compared with combinations that also included an anticoagulant agent could not be evaluated due to the small size of these subgroups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Importantly, there were no major bleeding events observed in the dual antiplatelet or single antiplatelet groups.</p><p></p><p class="headingAnchor" id="H593668338"><span class="h3">Our approach after venous stenting</span><span class="headingEndMark"> — </span>For patients who undergo<strong> venous stenting, </strong>we use the following approach [<a href="#rid2">2,10,50</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with<strong> acute/subacute thrombotic iliocaval lesions</strong>, we continue anticoagulation after thrombolysis. Parenteral anticoagulation should be resumed within four hours after sheath removal and transitioned to oral anticoagulation. Therapeutic anticoagulation is continued using dosing, duration and monitoring per VTE guidelines [<a href="#rid2">2,88,89</a>]. Generally, anticoagulation can be discontinued (typically after six months) when the underlying anatomic venous pathology provoked the thrombotic event and after satisfactory imaging of the iliocaval segment shows complete resolution of the clot burden and the underlying stenosis. Immediately after stent placement, we provide a 300 mg oral loading dose of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> and continue clopidogrel 75 mg daily for three months, after which we discontinue clopidogrel and give <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 81 mg daily indefinitely. Antiplatelet therapy is individualized in those with an increased risk for bleeding. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with <strong>recurrent thrombotic iliocaval lesions</strong>, parenteral anticoagulation should be resumed within four hours after sheath removal and transitioned to oral anticoagulation. Therapeutic anticoagulation is continued indefinitely given the high risk of thrombosis [<a href="#rid2">2,88,89</a>]. Immediately after stent placement, we provide a 300 mg oral loading dose of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> and continue clopidogrel 75 mg daily for three months after which we discontinue clopidogrel and give <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 81 mg daily indefinitely. Antiplatelet therapy is individualized accordingly for those with an increased risk for bleeding. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with <strong>nonthrombotic lesions</strong> (eg, May-Thurner syndrome, chronic venous changes), immediately after stent placement, we provide a 300 mg oral loading dose of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>. For patients at low risk for bleeding, we suggest dual antiplatelet therapy using clopidogrel (75 mg daily) and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 81 mg for four to six weeks, after which we discontinue clopidogrel and continue aspirin indefinitely. Antiplatelet therapy is individualized for those at an increased risk for bleeding. </p><p></p><p class="headingAnchor" id="H2337957579"><span class="h2">Compression hosiery</span><span class="headingEndMark"> — </span>Patients are instructed to use graded compression stockings as part of their daily routine [<a href="#rid2">2</a>]. Following successful intervention for symptomatic ICVO and to help reduce the incidence of post-thrombotic syndrome, we prescribe knee or thigh-high compression stockings (30 to 40 mmHg) for at least two years and indefinitely, if tolerated [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency"</a> and  <a class="medical medical_review" href="/z/d/html/8200.html" rel="external">"Post-thrombotic (postphlebitic) syndrome"</a>.)</p><p class="headingAnchor" id="H4100113097"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Under most circumstances, treatment of iliocaval venous obstruction (ICVO) will improve hemodynamics, most symptoms related to venous hypertension, as well as quality-of-life (QOL) [<a href="#rid35">35,101-105</a>]. Outcomes in patients with ICVO related to May-Thurner syndrome are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/110055.html" rel="external">"May-Thurner syndrome", section on 'Efficacy of endovenous therapy'</a>.)</p><p>Complications of endovascular therapy include bleeding related to the use of thrombolytic agents and complications related to the placement of venous stents, which include the following: "jailing" the contralateral common iliac vein, which can lead to thrombosis [<a href="#rid68">68,77</a>]; rupture of the iliac vein; stent migration or displacement; and erosion of stent into an overlying artery. </p><p class="headingAnchor" id="H1093822323"><span class="h2">Patency and reintervention</span><span class="headingEndMark"> — </span>Initial technical success for the treatment of iliocaval lesions in most series is high, with one-year patency rates (primary, assisted) greater than 90 percent  (<a class="graphic graphic_table graphicRef116568" href="/z/d/graphic/116568.html" rel="external">table 1</a>) [<a href="#rid35">35,106,107</a>]. </p><p>The patency of stents used to treat nonthrombotic lesions appears to be better compared with post-thrombotic disease [<a href="#rid75">75,108,109</a>]. In a review that included 982 obstructive lesions, the primary, assisted primary, and secondary cumulative patency rates were 79, 100, and 100 percent for patients with nonthrombotic disease compared with 57, 80, and 86 percent for patients with thrombotic disease, respectively [<a href="#rid75">75</a>]. Severe in-stent restenosis (&gt;50 percent) has been observed in 5 to 15 percent of limbs after iliofemoral venous stenting [<a href="#rid61">61,75</a>]. In one study, the cumulative, overall rate of severe in-stent restenosis was 5 percent at 72 months, but significantly higher in thrombotic compared with nonthrombotic limbs (10 versus 1 percent)  (<a class="graphic graphic_diagnosticimage graphicRef116563" href="/z/d/graphic/116563.html" rel="external">image 11</a>) [<a href="#rid61">61</a>]. </p><p>Stent occlusion after IVCO stenting is a rare occurrence. Of the patients who have undergone iliofemoral venous stenting, 5 to 20 percent may require reintervention for in-stent restenosis with or without stent compression [<a href="#rid110">110-112</a>]. Reintervention for in-stent restenosis has been associated with good and durable relief of symptoms with cumulative improvement in pain and swelling at 18 months after reintervention for stenosis &gt;60 percent [<a href="#rid113">113</a>]. In a large retrospective study, the primary, primary-assisted, and secondary patency at 60 months after reintervention for in-stent restenosis was 70, 98, and 84 percent, respectively [<a href="#rid112">112</a>]. </p><p class="headingAnchor" id="H3123942490"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>Many studies have highlighted the socioeconomic burden of post-thrombotic syndrome (PTS) on QOL [<a href="#rid3">3,114-117</a>]. Endovenous intervention for ICVO is associated with reduced severity of PTS symptoms and improved quality of life [<a href="#rid118">118</a>]. In a study of 938 patients with chronic ICVO with and without venous reflux, complete relief of pain was achieved in 82 and 77 percent of patients, respectively [<a href="#rid119">119</a>]. In addition, complete relief of swelling occurred in 47 and 53 percent, respectively; stasis ulcer healing in 67 and 76 percent, respectively; and overall clinical improvement in 75 and 79 percent, respectively. </p><p>Some studies have suggested using the Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ) to provide a subjective analysis of pain, sleep disturbance, morale, and social activities, including routine and strenuous physical activities, before and after intervention. The CIVIQ assessment has proven to be specific and relevant to chronic venous disease. In several reviews, CIVIQ improved significantly after intervention (doubled in three of the five indicated categories) [<a href="#rid75">75,104,120</a>]. There is also a direct correlation between quality-of-life and revised Venous Clinical Severity Score (VCSS) (<a class="calc calc_professional" href="/z/d/html/13453.html" rel="external">calculator 1</a>). Improved QOL can also be demonstrated in those with improved Short Form (36) Health Survey (SF-36) scores, and Venous Insufficiency Epidemiologic and Economic Study quality-of-life questionnaire (VEINES-QOL) scores and its validated subscale of 10 items on venous symptoms (VEINES-Sym) scores [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/z/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Measures of clinical severity'</a> and  <a class="medical medical_review" href="/z/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Disease-specific quality-of-life measures'</a>.)</p><p class="headingAnchor" id="H1312598728"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118466.html" rel="external">"Society guideline links: Chronic venous disorders"</a>.)</p><p class="headingAnchor" id="H1823463574"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Iliocaval venous obstruction (ICVO) is an underrecognized venous pathology with an increasing incidence. Proceeding with endovenous treatment of ICVO depends upon the severity of symptoms and whether thrombus is present (ie, nonthrombotic ICVO, thrombotic ICVO). (See  <a class="medical medical_review" href="/z/d/html/15223.html" rel="external">"Overview of iliocaval venous obstruction", section on 'Approach to venous intervention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with moderate-to-severe symptoms related to nonthrombotic ICVO, treatment is targeted toward reducing the severity of the chronic venous stenosis/occlusion. Restoring patency of the venous outflow reduces swelling, aids healing of ulcers (if present), and improves overall quality of life. (See <a class="local">'Angioplasty/stenting'</a> above and <a class="local">'Outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with thrombotic ICVO and appropriate indications for treatment, we suggest pharmacomechanical thrombolysis rather than catheter-directed thrombolysis alone or percutaneous mechanical thrombectomy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The added benefit of mechanical thrombolysis is to fractionate the load of the thrombus to facilitate the pharmacologic thrombolysis. Pharmacomechanical thrombolysis reduces the dose of the thrombolytic agent and reduces hospital stay and intensive care unit utilization. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with stenotic ICVO lesions (May-Thurner syndrome, chronic venous changes), we suggest angioplasty and stenting, rather than angioplasty alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Angioplasty alone is associated with higher rates of recurrent stenosis and thrombosis. (See <a class="local">'Angioplasty/stenting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to antithrombotic therapy following iliocaval venous intervention is as follows: (See <a class="local">'Antithrombotic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with <strong>acute</strong> iliocaval venous thrombosis (ie, thrombotic) should receive therapeutic anticoagulation with dosing, and duration as per venous thromboembolism (VTE) guidelines. (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at low risk of bleeding'</a>.)</p><p></p><p class="bulletIndent2">In addition: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who undergo venous angioplasty, but no stent has been deployed, we suggest <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (81 mg) daily, rather than no antiplatelet therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients at low risk for bleeding, after stenting we suggest monotherapy using <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> alone for a period of four to six weeks, rather than no therapy or dual antiplatelet therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Thereafter, we suggest <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> indefinitely, rather than no antiplatelet therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Our approach after venous stenting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with <strong>chronic</strong> iliocaval lesion (ie, nonthrombotic; May-Thurner, chronic post-thrombotic changes) at low risk for bleeding, after stenting we suggest dual antiplatelet therapy using <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for four to six weeks, rather than monotherapy or no therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Thereafter, we suggest aspirin indefinitely, rather than no antiplatelet therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Our approach after venous stenting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an increased risk for bleeding, antiplatelet therapy after iliocaval venous stenting is individualized, but often consists of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone. For all patients, we avoid triple antithrombotic therapy (ie, anticoagulation and dual antiplatelet therapy) because of its inherent increased risk of major bleeding. (See <a class="local">'Antithrombotic therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mousa AY, AbuRahma AF. May-Thurner syndrome: update and review. Ann Vasc Surg 2013; 27:984.</a></li><li><a class="nounderline abstract_t">Meissner MH, Gloviczki P, Comerota AJ, et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2012; 55:1449.</a></li><li><a class="nounderline abstract_t">Casey ET, Murad MH, Zumaeta-Garcia M, et al. Treatment of acute iliofemoral deep vein thrombosis. J Vasc Surg 2012; 55:1463.</a></li><li><a class="nounderline abstract_t">Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379:31.</a></li><li><a class="nounderline abstract_t">Laiho MK, Oinonen A, Sugano N, et al. Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis. Eur J Vasc Endovasc Surg 2004; 28:391.</a></li><li><a class="nounderline abstract_t">Robertson L, McBride O, Burdess A. Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis. Cochrane Database Syst Rev 2016; 11:CD011536.</a></li><li><a class="nounderline abstract_t">Sharifi M, Bay C, Mehdipour M, et al. Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trial: midterm results. J Endovasc Ther 2012; 19:273.</a></li><li><a class="nounderline abstract_t">Srinivas BC, Patra S, Nagesh CM, et al. Catheter-Directed Thrombolysis Along with Mechanical Thromboaspiration versus Anticoagulation Alone in the Management of Lower Limb Deep Venous Thrombosis-A Comparative Study. Int J Angiol 2014; 23:247.</a></li><li><a class="nounderline abstract_t">Cakir V, Gulcu A, Akay E, et al. Use of percutaneous aspiration thrombectomy vs. anticoagulation therapy to treat acute iliofemoral venous thrombosis: 1-year follow-up results of a randomised, clinical trial. Cardiovasc Intervent Radiol 2014; 37:969.</a></li><li><a class="nounderline abstract_t">Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.</a></li><li><a class="nounderline abstract_t">Bashir R, Zack CJ, Zhao H, et al. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. JAMA Intern Med 2014; 174:1494.</a></li><li><a class="nounderline abstract_t">Ferris EJ, Lim WN, Smith PL, Casali R. May-Thurner syndrome. Radiology 1983; 147:29.</a></li><li><a class="nounderline abstract_t">Labropoulos N, Borge M, Pierce K, Pappas PJ. Criteria for defining significant central vein stenosis with duplex ultrasound. J Vasc Surg 2007; 46:101.</a></li><li><a class="nounderline abstract_t">Ahmed HK, Hagspiel KD. Intravascular ultrasonographic findings in May-Thurner syndrome (iliac vein compression syndrome). J Ultrasound Med 2001; 20:251.</a></li><li><a class="nounderline abstract_t">Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2014; :CD002783.</a></li><li><a class="nounderline abstract_t">McLafferty RB. Evidence of prevention and treatment of postthrombotic syndrome. J Vasc Surg 2010; 52:69S.</a></li><li><a class="nounderline abstract_t">Henke P, Writing Group I of the Pacific Vascular Symposium 6, Vandy F, et al. Prevention and treatment of the postthrombotic syndrome. J Vasc Surg 2010; 52:21S.</a></li><li><a class="nounderline abstract_t">Zhu QH, Zhou CY, Chen Y, et al. Percutaneous manual aspiration thrombectomy followed by stenting for iliac vein compression syndrome with secondary acute isolated iliofemoral deep vein thrombosis: a prospective study of single-session endovascular protocol. Eur J Vasc Endovasc Surg 2014; 47:68.</a></li><li><a class="nounderline abstract_t">Ye K, Lu X, Li W, et al. Long-term outcomes of stent placement for symptomatic nonthrombotic iliac vein compression lesions in chronic venous disease. J Vasc Interv Radiol 2012; 23:497.</a></li><li><a class="nounderline abstract_t">Wilson JJ, Balsys A, Newman H, Lychacz B. IVC thrombosis: successful treatment with low dose streptokinase. J Cardiovasc Surg (Torino) 1992; 33:109.</a></li><li><a class="nounderline abstract_t">Ferket BS, Grootenboer N, Colkesen EB, et al. Systematic review of guidelines on abdominal aortic aneurysm screening. J Vasc Surg 2012; 55:1296.</a></li><li><a class="nounderline abstract_t">Soussou ID. Regarding "Iliac vein compression syndrome: case report and review of the literature". J Vasc Surg 1997; 25:957.</a></li><li><a class="nounderline abstract_t">Raju S. Long-term outcomes of stent placement for symptomatic nonthrombotic iliac vein compression lesions in chronic venous disease. J Vasc Interv Radiol 2012; 23:502.</a></li><li><a class="nounderline abstract_t">Olin JW, Graor RA, O'Hara P, Young JR. The incidence of deep venous thrombosis in patients undergoing abdominal aortic aneurysm resection. J Vasc Surg 1993; 18:1037.</a></li><li><a class="nounderline abstract_t">Raju S, Davis M. Relative Importance of Iliac Vein Obstruction in Patients with Post-Thrombotic Femoral Vein Occlusion. J Vasc Surg Venous Lymphat Disord 2014; 2:107.</a></li><li><a class="nounderline abstract_t">Vedantham S, Vesely TM, Parti N, et al. Lower extremity venous thrombolysis with adjunctive mechanical thrombectomy. J Vasc Interv Radiol 2002; 13:1001.</a></li><li><a class="nounderline abstract_t">Shah NG, Wible BC, Paulisin JA, et al. Management of inferior vena cava thrombosis with the FlowTriever and ClotTriever systems. J Vasc Surg Venous Lymphat Disord 2021; 9:615.</a></li><li><a class="nounderline abstract_t">Baker R, Samuels S, Benenati JF, et al. Ultrasound-accelerated vs standard catheter-directed thrombolysis--a comparative study in patients with iliofemoral deep vein thrombosis. J Vasc Interv Radiol 2012; 23:1460.</a></li><li><a class="nounderline abstract_t">Garcia MJ, Lookstein R, Malhotra R, et al. Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) Registry. J Vasc Interv Radiol 2015; 26:777.</a></li><li><a class="nounderline abstract_t">Park KM, Moon IS, Kim JI, et al. Mechanical thrombectomy with Trerotola compared with catheter-directed thrombolysis for treatment of acute iliofemoral deep vein thrombosis. Ann Vasc Surg 2014; 28:1853.</a></li><li><a class="nounderline abstract_t">Bertino FJ, Shin DS, Monroe EJ, et al. Thrombectomy of Malignant Thoracic Central Venous Occlusive Disease Using Inari ClotTriever System. J Vasc Interv Radiol 2021; 32:1398.</a></li><li><a class="nounderline abstract_t">Benarroch-Gampel J, Pujari A, Aizpuru M, et al. Technical success and short-term outcomes after treatment of lower extremity deep vein thrombosis with the ClotTriever system: A preliminary experience. J Vasc Surg Venous Lymphat Disord 2020; 8:174.</a></li><li><a class="nounderline abstract_t">Ciampi-Dopazo JJ, Romeu-Prieto JM, Sánchez-Casado M, et al. Aspiration Thrombectomy for Treatment of Acute Massive and Submassive Pulmonary Embolism: Initial Single-Center Prospective Experience. J Vasc Interv Radiol 2018; 29:101.</a></li><li><a class="nounderline abstract_t">Bisdas T, Stavroulakis K, Beropoulis E, et al. Initial Experience With the 6-F and 8-F Indigo Thrombectomy System for Acute Renovisceral Occlusive Events. J Endovasc Ther 2017; 24:604.</a></li><li><a class="nounderline abstract_t">Wang W, Sun R, Chen Y, Liu C. Meta-analysis and systematic review of percutaneous mechanical thrombectomy for lower extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 2018; 6:788.</a></li><li><a class="nounderline abstract_t">Kim HS, Patra A, Paxton BE, et al. Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes. J Vasc Interv Radiol 2006; 17:1099.</a></li><li><a class="nounderline abstract_t">Semba CP, Dake MD. Catheter-directed thrombolysis for iliofemoral venous thrombosis. Semin Vasc Surg 1996; 9:26.</a></li><li><a class="nounderline abstract_t">Bjarnason H, Kruse JR, Asinger DA, et al. Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol 1997; 8:405.</a></li><li><a class="nounderline abstract_t">Semba CP, Dake MD. Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. Radiology 1994; 191:487.</a></li><li><a class="nounderline abstract_t">Lin PH, Zhou W, Dardik A, et al. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis. Am J Surg 2006; 192:782.</a></li><li><a class="nounderline abstract_t">Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999; 211:39.</a></li><li><a class="nounderline abstract_t">Vedantham S, Vesely TM, Sicard GA, et al. Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis. J Vasc Interv Radiol 2004; 15:565.</a></li><li><a class="nounderline abstract_t">Reekers JA. Re: Current practice of temporary vena cava filter insertion: a multicenter registry. J Vasc Interv Radiol 2000; 11:1363.</a></li><li><a class="nounderline abstract_t">Lorch H, Welger D, Wagner V, et al. Current practice of temporary vena cava filter insertion: a multicenter registry. J Vasc Interv Radiol 2000; 11:83.</a></li><li><a class="nounderline abstract_t">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112:416.</a></li><li><a class="nounderline abstract_t">Lee SH, Kim HK, Hwang JK, et al. Efficacy of Retrievable Inferior Vena Cava Filter Placement in the Prevention of Pulmonary Embolism during Catheter-Directed Thrombectomy for Proximal Lower-Extremity Deep Vein Thrombosis. Ann Vasc Surg 2016; 33:181.</a></li><li><a class="nounderline abstract_t">Kölbel T, Alhadad A, Acosta S, et al. Thrombus embolization into IVC filters during catheter-directed thrombolysis for proximal deep venous thrombosis. J Endovasc Ther 2008; 15:605.</a></li><li><a class="nounderline abstract_t">Sharifi M, Bay C, Skrocki L, et al. Role of IVC filters in endovenous therapy for deep venous thrombosis: the FILTER-PEVI (filter implantation to lower thromboembolic risk in percutaneous endovenous intervention) trial. Cardiovasc Intervent Radiol 2012; 35:1408.</a></li><li><a class="nounderline abstract_t">Sharifi M, Mehdipour M, Bay C, et al. Endovenous therapy for deep venous thrombosis: the TORPEDO trial. Catheter Cardiovasc Interv 2010; 76:316.</a></li><li><a class="nounderline abstract_t">Protack CD, Bakken AM, Patel N, et al. Long-term outcomes of catheter directed thrombolysis for lower extremity deep venous thrombosis without prophylactic inferior vena cava filter placement. J Vasc Surg 2007; 45:992.</a></li><li><a class="nounderline abstract_t">Arko FR, Davis CM 3rd, Murphy EH, et al. Aggressive percutaneous mechanical thrombectomy of deep venous thrombosis: early clinical results. Arch Surg 2007; 142:513.</a></li><li><a class="nounderline abstract_t">Vedantham S, Sista AK, Klein SJ, et al. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol 2014; 25:1317.</a></li><li><a class="nounderline abstract_t">Rao AS, Konig G, Leers SA, et al. Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis: an alternative in patients with contraindications to thrombolysis. J Vasc Surg 2009; 50:1092.</a></li><li><a class="nounderline abstract_t">Graif A, Grilli CJ, Kimbiris G, et al. Evaluation of Fibrinogen Levels during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism. J Vasc Interv Radiol 2020; 31:1281.</a></li><li><a class="nounderline abstract_t">Sista AK. Fibrinogen Monitoring during Catheter-Directed Thrombolysis for Pulmonary Embolism: Can It Be Cleaved from Our Practice? J Vasc Interv Radiol 2020; 31:1290.</a></li><li><a class="nounderline abstract_t">Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991; 115:256.</a></li><li><a class="nounderline abstract_t">Robertson I, Kessel DO, Berridge DC. Fibrinolytic agents for peripheral arterial occlusion. Cochrane Database Syst Rev 2013; :CD001099.</a></li><li><a class="nounderline abstract_t">Sebastian T, Dopheide JF, Engelberger RP, et al. Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents. J Vasc Surg Venous Lymphat Disord 2018; 6:312.</a></li><li><a class="nounderline abstract_t">Fraser DG, Moody AR, Morgan PS, Martel A. Iliac compression syndrome and recanalization of femoropopliteal and iliac venous thrombosis: a prospective study with magnetic resonance venography. J Vasc Surg 2004; 40:612.</a></li><li><a class="nounderline abstract_t">Neglén P, Raju S. Proximal lower extremity chronic venous outflow obstruction: recognition and treatment. Semin Vasc Surg 2002; 15:57.</a></li><li><a class="nounderline abstract_t">Neglén P, Raju S. In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract. J Vasc Surg 2004; 39:181.</a></li><li><a class="nounderline abstract_t">Neglén P, Raju S. Balloon dilation and stenting of chronic iliac vein obstruction: technical aspects and early clinical outcome. J Endovasc Ther 2000; 7:79.</a></li><li><a class="nounderline abstract_t">Raju S, McAllister S, Neglen P. Recanalization of totally occluded iliac and adjacent venous segments. J Vasc Surg 2002; 36:903.</a></li><li><a class="nounderline abstract_t">Raju S, Hollis K, Neglen P. Obstructive lesions of the inferior vena cava: clinical features and endovenous treatment. J Vasc Surg 2006; 44:820.</a></li><li><a class="nounderline abstract_t">Seager MJ, Busuttil A, Dharmarajah B, Davies AH. Editor's Choice-- A Systematic Review of Endovenous Stenting in Chronic Venous Disease Secondary to Iliac Vein Obstruction. Eur J Vasc Endovasc Surg 2016; 51:100.</a></li><li><a class="nounderline abstract_t">Mickley V, Schwagierek R, Rilinger N, et al. Left iliac venous thrombosis caused by venous spur: treatment with thrombectomy and stent implantation. J Vasc Surg 1998; 28:492.</a></li><li><a class="nounderline abstract_t">Comerota AJ, Grewal N, Martinez JT, et al. Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. J Vasc Surg 2012; 55:768.</a></li><li><a class="nounderline abstract_t">Gloviczki P, Lawrence PF. Iliac vein stenting and contralateral deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 2017; 5:5.</a></li><li><a class="nounderline abstract_t">Williams ZF, Dillavou ED. A systematic review of venous stents for iliac and venacaval occlusive disease. J Vasc Surg Venous Lymphat Disord 2020; 8:145.</a></li><li><a class="nounderline abstract_t">Lichtenberg M, Breuckmann F, Stahlhoff WF, et al. Placement of closed-cell designed venous stents in a mixed cohort of patients with chronic venous outflow obstructions - short-term safety, patency, and clinical outcomes. Vasa 2018; 47:475.</a></li><li><a class="nounderline abstract_t">Razavi MK, Black S, Gagne P, et al. Pivotal Study of Endovenous Stent Placement for Symptomatic Iliofemoral Venous Obstruction. Circ Cardiovasc Interv 2019; 12:e008268.</a></li><li><a class="nounderline abstract_t">Hejazi M, Phani AS, Gagnon J, et al. Deformation characteristics of venous stents: a comparative assessment. J Vasc Surg 2018; 68:e84.</a></li><li><a class="nounderline abstract_t">Kumar S, Miller M, Wood E, et al. Secondary interventions after vein stent placements: Why do venous stents fail. J Vasc Surg 2018; 68:e23.</a></li><li><a class="nounderline abstract_t">Meissner MH. Indications for platelet aggregation inhibitors after venous stents. Phlebology 2013; 28 Suppl 1:91.</a></li><li><a class="nounderline abstract_t">Neglén P, Hollis KC, Olivier J, Raju S. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. J Vasc Surg 2007; 46:979.</a></li><li><a class="nounderline abstract_t">Caliste XA, Clark AL, Doyle AJ, et al. The incidence of contralateral iliac venous thrombosis after stenting across the iliocaval confluence in patients with acute or chronic venous outflow obstruction. J Vasc Surg Venous Lymphat Disord 2014; 2:253.</a></li><li><a class="nounderline abstract_t">Khairy SA, Neves RJ, Hartung O, O'Sullivan GJ. Factors Associated with Contralateral Deep Venous Thrombosis after Iliocaval Venous Stenting. Eur J Vasc Endovasc Surg 2017; 54:745.</a></li><li><a class="nounderline abstract_t">Murphy EH, Johns B, Varney E, et al. Deep venous thrombosis associated with caval extension of iliac stents. J Vasc Surg Venous Lymphat Disord 2017; 5:8.</a></li><li><a class="nounderline abstract_t">Neglén P, Darcey R, Olivier J, Raju S. Bilateral stenting at the iliocaval confluence. J Vasc Surg 2010; 51:1457.</a></li><li><a class="nounderline abstract_t">Zhang X, Jing Y, Sang H, et al. Long-term follow-up of the stenting across the iliocaval confluence in patients with iliac venous lesions. J Thromb Thrombolysis 2019; 47:134.</a></li><li><a class="nounderline abstract_t">Duarte-Gamas L, Rocha-Neves JP, Pereira-Neves A, et al. Contralateral deep vein thrombosis after stenting across the iliocaval confluence in chronic venous disease - A systematic review. Phlebology 2020; 35:221.</a></li><li><a class="nounderline abstract_t">Ramos J, Hwang S, Berger K, et al. Iliocaval venous anomalies encountered during vein stenting for proximal iliac outflow obstruction. J Vasc Surg 2020; 72:e242.</a></li><li><a class="nounderline abstract_t">Eijgenraam P, ten Cate H, ten Cate-Hoek AJ. Venous stenting after deep venous thrombosis and antithrombotic therapy: a systematic review. Reviews in Vascular Medicine 2014; 2:88.</a></li><li><a class="nounderline abstract_t">Attaran RR, Ozdemir D, Lin IH, et al. Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion. J Vasc Surg Venous Lymphat Disord 2019; 7:527.</a></li><li><a class="nounderline abstract_t">Mahnken AH, Thomson K, de Haan M, O'Sullivan GJ. CIRSE standards of practice guidelines on iliocaval stenting. Cardiovasc Intervent Radiol 2014; 37:889.</a></li><li><a class="nounderline abstract_t">Razavi MK, Jaff MR, Miller LE. Safety and Effectiveness of Stent Placement for Iliofemoral Venous Outflow Obstruction: Systematic Review and Meta-Analysis. Circ Cardiovasc Interv 2015; 8:e002772.</a></li><li><a class="nounderline abstract_t">Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus. Eur J Vasc Endovasc Surg 2018; 55:537.</a></li><li><a class="nounderline abstract_t">Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.</a></li><li><a class="nounderline abstract_t">Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123:1788.</a></li><li><a class="nounderline abstract_t">Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451:914.</a></li><li><a class="nounderline abstract_t">Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92:3041.</a></li><li><a class="nounderline abstract_t">Deiner C, Loddenkemper C, Rauch U, et al. Mechanisms of late lumen loss after antiproliferative percutaneous coronary intervention using beta-irradiation in a porcine model of restenosis. Cardiovasc Revasc Med 2007; 8:94.</a></li><li><a class="nounderline abstract_t">Nakatani M, Takeyama Y, Shibata M, et al. Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 2003; 12:40.</a></li><li><a class="nounderline abstract_t">Mitra AK, Gangahar DM, Agrawal DK. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006; 84:115.</a></li><li><a class="nounderline abstract_t">Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 2015; 61:2S.</a></li><li><a class="nounderline abstract_t">Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.</a></li><li><a class="nounderline abstract_t">Singh P, Harper Y, Oliphant CS, et al. Peripheral interventions and antiplatelet therapy: Role in current practice. World J Cardiol 2017; 9:583.</a></li><li><a class="nounderline abstract_t">Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. Catheter Cardiovasc Interv 2012; 79:501.</a></li><li><a class="nounderline abstract_t">Endo M, Jahangiri Y, Horikawa M, et al. Antiplatelet Therapy is Associated with Stent Patency After Iliocaval Venous Stenting. Cardiovasc Intervent Radiol 2018; 41:1691.</a></li><li><a class="nounderline abstract_t">Lin C, Martin KA, Wang M, et al. Long-term antithrombotic therapy after venous stent placement. Phlebology 2020; 35:402.</a></li><li><a class="nounderline abstract_t">Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2016; 11:CD002783.</a></li><li><a class="nounderline abstract_t">Hartung O, Otero A, Boufi M, et al. Mid-term results of endovascular treatment for symptomatic chronic nonmalignant iliocaval venous occlusive disease. J Vasc Surg 2005; 42:1138.</a></li><li><a class="nounderline abstract_t">Alhadad A, Kölbel T, Herbst A, et al. Iliocaval vein stenting: Long term survey of postthrombotic symptoms and working capacity. J Thromb Thrombolysis 2011; 31:211.</a></li><li><a class="nounderline abstract_t">Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life. Ann Surg 2004; 239:118.</a></li><li><a class="nounderline abstract_t">Comerota AJ, Kearon C, Gu CS, et al. Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. Circulation 2019; 139:1162.</a></li><li><a class="nounderline abstract_t">O'Sullivan GJ, Semba CP, Bittner CA, et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. J Vasc Interv Radiol 2000; 11:823.</a></li><li><a class="nounderline abstract_t">Hurst DR, Forauer AR, Bloom JR, et al. Diagnosis and endovascular treatment of iliocaval compression syndrome. J Vasc Surg 2001; 34:106.</a></li><li><a class="nounderline abstract_t">Sebastian T, Spirk D, Engelberger RP, et al. Incidence of Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with the Postthrombotic Syndrome. Thromb Haemost 2019; 119:2064.</a></li><li><a class="nounderline abstract_t">Raju S, Owen S Jr, Neglen P. The clinical impact of iliac venous stents in the management of chronic venous insufficiency. J Vasc Surg 2002; 35:8.</a></li><li><a class="nounderline abstract_t">Hartung O, Loundou AD, Barthelemy P, et al. Endovascular management of chronic disabling ilio-caval obstructive lesions: long-term results. Eur J Vasc Endovasc Surg 2009; 38:118.</a></li><li><a class="nounderline abstract_t">Raju S, Tackett P Jr, Neglen P. Reinterventions for nonocclusive iliofemoral venous stent malfunctions. J Vasc Surg 2009; 49:511.</a></li><li><a class="nounderline abstract_t">Jayaraj A, Fuller R, Raju S, Stafford J. In-stent restenosis and stent compression following stenting for chronic iliofemoral venous obstruction. J Vasc Surg Venous Lymphat Disord 2022; 10:42.</a></li><li><a class="nounderline abstract_t">Saleem T, Raju S. An overview of in-stent restenosis in iliofemoral venous stents. J Vasc Surg Venous Lymphat Disord 2022; 10:492.</a></li><li><a class="nounderline abstract_t">Kahn SR. The post-thrombotic syndrome: progress and pitfalls. Br J Haematol 2006; 134:357.</a></li><li><a class="nounderline abstract_t">Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002; 162:1144.</a></li><li><a class="nounderline abstract_t">Hood DB, Weaver FA, Modrall JG, Yellin AE. Advances in the treatment of phlegmasia cerulea dolens. Am J Surg 1993; 166:206.</a></li><li><a class="nounderline abstract_t">Tung CS, Soliman PT, Wallace MJ, et al. Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens. Gynecol Oncol 2007; 107:140.</a></li><li><a class="nounderline abstract_t">Heniford BT, Senler SO, Olsofka JM, et al. May-Thurner syndrome: management by endovascular surgical techniques. Ann Vasc Surg 1998; 12:482.</a></li><li><a class="nounderline abstract_t">Raju S, Neglen P. High prevalence of nonthrombotic iliac vein lesions in chronic venous disease: a permissive role in pathogenicity. J Vasc Surg 2006; 44:136.</a></li><li><a class="nounderline abstract_t">Launois R, Reboul-Marty J, Henry B. Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). Qual Life Res 1996; 5:539.</a></li></ol></div><div id="topicVersionRevision">Topic 15222 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23850314" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : May-Thurner syndrome: update and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22469503" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440631" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of acute iliofemoral deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22172244" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15350561" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27814432" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22545895" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trial: midterm results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25484556" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Catheter-Directed Thrombolysis Along with Mechanical Thromboaspiration versus Anticoagulation Alone in the Management of Lower Limb Deep Venous Thrombosis-A Comparative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24934734" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of percutaneous aspiration thrombectomy vs. anticoagulation therapy to treat acute iliofemoral venous thrombosis: 1-year follow-up results of a randomised, clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574272" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25047081" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6828755" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : May-Thurner syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17540535" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Criteria for defining significant central vein stenosis with duplex ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11270529" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intravascular ultrasonographic findings in May-Thurner syndrome (iliac vein compression syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24452314" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thrombolysis for acute deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21077274" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evidence of prevention and treatment of postthrombotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20678879" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevention and treatment of the postthrombotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183245" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Percutaneous manual aspiration thrombectomy followed by stenting for iliac vein compression syndrome with secondary acute isolated iliofemoral deep vein thrombosis: a prospective study of single-session endovascular protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22342482" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term outcomes of stent placement for symptomatic nonthrombotic iliac vein compression lesions in chronic venous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1544988" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : IVC thrombosis: successful treatment with low dose streptokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324630" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Systematic review of guidelines on abdominal aortic aneurysm screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9152329" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Regarding "Iliac vein compression syndrome: case report and review of the literature".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464715" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term outcomes of stent placement for symptomatic nonthrombotic iliac vein compression lesions in chronic venous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8264032" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The incidence of deep venous thrombosis in patients undergoing abdominal aortic aneurysm resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26992988" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Relative Importance of Iliac Vein Obstruction in Patients with Post-Thrombotic Femoral Vein Occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12397121" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lower extremity venous thrombolysis with adjunctive mechanical thrombectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33045392" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Management of inferior vena cava thrombosis with the FlowTriever and ClotTriever systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23101918" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ultrasound-accelerated vs standard catheter-directed thrombolysis--a comparative study in patients with iliofemoral deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25824314" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25011091" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mechanical thrombectomy with Trerotola compared with catheter-directed thrombolysis for treatment of acute iliofemoral deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34062273" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Thrombectomy of Malignant Thoracic Central Venous Occlusive Disease Using Inari ClotTriever System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843476" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Technical success and short-term outcomes after treatment of lower extremity deep vein thrombosis with the ClotTriever system: A preliminary experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29102272" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Aspiration Thrombectomy for Treatment of Acute Massive and Submassive Pulmonary Embolism: Initial Single-Center Prospective Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28548010" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Initial Experience With the 6-F and 8-F Indigo Thrombectomy System for Acute Renovisceral Occlusive Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30336908" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Meta-analysis and systematic review of percutaneous mechanical thrombectomy for lower extremity deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868161" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8665023" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Catheter-directed thrombolysis for iliofemoral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9152914" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8153327" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161094" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189452" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178716" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099250" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Re: Current practice of temporary vena cava filter insertion: a multicenter registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10693718" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Current practice of temporary vena cava filter insertion: a multicenter registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009794" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26806235" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of Retrievable Inferior Vena Cava Filter Placement in the Prevention of Pulmonary Embolism during Catheter-Directed Thrombectomy for Proximal Lower-Extremity Deep Vein Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840047" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Thrombus embolization into IVC filters during catheter-directed thrombolysis for proximal deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271078" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Role of IVC filters in endovenous therapy for deep venous thrombosis: the FILTER-PEVI (filter implantation to lower thromboembolic risk in percutaneous endovenous intervention) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578224" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Endovenous therapy for deep venous thrombosis: the TORPEDO trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17466791" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term outcomes of catheter directed thrombolysis for lower extremity deep venous thrombosis without prophylactic inferior vena cava filter placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576886" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Aggressive percutaneous mechanical thrombectomy of deep venous thrombosis: early clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25000825" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19782528" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis: an alternative in patients with contraindications to thrombolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32703545" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evaluation of Fibrinogen Levels during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32624342" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fibrinogen Monitoring during Catheter-Directed Thrombolysis for Pulmonary Embolism: Can It Be Cleaved from Our Practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906692" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357258" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Fibrinolytic agents for peripheral arterial occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29550177" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472585" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Iliac compression syndrome and recanalization of femoropopliteal and iliac venous thrombosis: a prospective study with magnetic resonance venography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11840427" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Proximal lower extremity chronic venous outflow obstruction: recognition and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718837" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821093" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Balloon dilation and stenting of chronic iliac vein obstruction: technical aspects and early clinical outcome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12422099" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recanalization of totally occluded iliac and adjacent venous segments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926084" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Obstructive lesions of the inferior vena cava: clinical features and endovenous treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26464055" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Editor's Choice-- A Systematic Review of Endovenous Stenting in Chronic Venous Disease Secondary to Iliac Vein Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737459" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Left iliac venous thrombosis caused by venous spur: treatment with thrombectomy and stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22277690" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27987610" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Iliac vein stenting and contralateral deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699668" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A systematic review of venous stents for iliac and venacaval occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30175948" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Placement of closed-cell designed venous stents in a mixed cohort of patients with chronic venous outflow obstructions - short-term safety, patency, and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31833414" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pivotal Study of Endovenous Stent Placement for Symptomatic Iliofemoral Venous Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Deformation characteristics of venous stents: a comparative assessment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Secondary interventions after vein stent placements: Why do venous stents fail</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23482542" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Indications for platelet aggregation inhibitors after venous stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980284" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26993383" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The incidence of contralateral iliac venous thrombosis after stenting across the iliocaval confluence in patients with acute or chronic venous outflow obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886989" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Factors Associated with Contralateral Deep Venous Thrombosis after Iliocaval Venous Stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27987616" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Deep venous thrombosis associated with caval extension of iliac stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385465" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bilateral stenting at the iliocaval confluence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30328053" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term follow-up of the stenting across the iliocaval confluence in patients with iliac venous lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31793374" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Contralateral deep vein thrombosis after stenting across the iliocaval confluence in chronic venous disease - A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Iliocaval venous anomalies encountered during vein stenting for proximal iliac outflow obstruction</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Venous stenting after deep venous thrombosis and antithrombotic therapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31203859" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633533" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : CIRSE standards of practice guidelines on iliocaval stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438686" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Safety and Effectiveness of Stent Placement for Iliofemoral Venous Outflow Obstruction: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29449145" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315268" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422387" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18288180" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Triggers, targets and treatments for thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586275" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17574167" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Mechanisms of late lumen loss after antiproliferative percutaneous coronary intervention using beta-irradiation in a porcine model of restenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12598017" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16519729" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638515" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315275" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28824788" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Peripheral interventions and antiplatelet therapy: Role in current practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21960485" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30120531" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Antiplatelet Therapy is Associated with Stent Patency After Iliocaval Venous Stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31821779" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Long-term antithrombotic therapy after venous stent placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27830895" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Thrombolysis for acute deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376204" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Mid-term results of endovascular treatment for symptomatic chronic nonmalignant iliocaval venous occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20640483" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Iliocaval vein stenting: Long term survey of postthrombotic symptoms and working capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14685109" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586751" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928517" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Endovascular management of iliac vein compression (May-Thurner) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11436082" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Diagnosis and endovascular treatment of iliocaval compression syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31659739" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Incidence of Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with the Postthrombotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11802127" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The clinical impact of iliac venous stents in the management of chronic venous insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356954" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Endovascular management of chronic disabling ilio-caval obstructive lesions: long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945579" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Reinterventions for nonocclusive iliofemoral venous stent malfunctions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34174500" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : In-stent restenosis and stent compression following stenting for chronic iliofemoral venous obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34774813" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : An overview of in-stent restenosis in iliofemoral venous stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16822286" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The post-thrombotic syndrome: progress and pitfalls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020185" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8352417" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Advances in the treatment of phlegmasia cerulea dolens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17669477" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732429" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : May-Thurner syndrome: management by endovascular surgical techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16828437" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : High prevalence of nonthrombotic iliac vein lesions in chronic venous disease: a permissive role in pathogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8993100" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
